Technical Articles

生物素标记食蟹猴PD-1蛋白是什么?食蟹猴种属与生物素位点如何改变临床前判读
What Biotinylated Cynomolgus PD-1 Changes in Preclinical Reading: Species and Biotinylation Site
发布时间 2026-11-18
Cynomolgus PD-1 sits between human and mouse readouts, and the Avi-tag biotin site fixes probe orientation. This article maps how both change interpretation.
View details
  • Immunity/Inflamma
  • biotinylated PD-1
  • PD-1
  • cynomolgus
  • Avi Tag
  • streptavidin
  • cross-reactivity
  • UA010811
重组人pd-1蛋白是什么?一个 IgV 结构域怎么管住 T 细胞的刹车
Human PD-1: How One IgV Domain Acts as the Brake on T Cell Activation
发布时间 2026-11-04
PD-1 is an immune-checkpoint receptor whose single IgV domain engages PD-L1/PD-L2 through ITIM/ITSM signaling. This article maps the molecular braking mechanism.
View details
  • Immunity/Inflamma
  • PD-1
  • PDCD1
  • CD279
  • IgV domain
  • ITIM
  • ITSM
  • PD-L1
  • UA010004
全球 PD-L1 抗体临床开发新趋势:组合、规模与区域突破
New Trends in Global PD-L1 Antibody Clinical Development: Combination, Scale, and Regional Breakthroughs
发布时间 2025-08-20
PD-L1 targeted antibodies, as the core force of tumor immunotherapy, restore the killing ability of T cells against tumors by blocking the immunosuppressive binding of PD-L1 and PD-1. Currently, it has become the standard treatment for 16 specific cancers and unlimited indications.
View details
  • Cancer
  • PD-1
  • PD-L1
  • Tumor
  • immunity
PD-1 免疫治疗全景:从机制突破到临床新探索
Panorama of PD-1 Immunotherapy: From Mechanism Breakthrough to Clinical New Exploration
发布时间 2025-08-20
Programmed death receptor 1 (PD-1) is a core member of the immune checkpoint family, mainly expressed on the surface of activated immune cells. It transmits immunosuppressive signals by binding to PD-L1/PD-L2, maintaining peripheral immune tolerance. But tumor cells often overexpress PD-L1 and achieve "immune escape" through the PD-1 pathway. Inhibitors targeting PD-1/PD-L1 have become a revolutionary approach in cancer treatment, and in recent years, research has expanded to include factors affecting efficacy, combination therapy, new mechanisms, and other dimensions, providing new directions for precision immunotherapy
View details
  • Immunity/Inflamma
  • PD-1
  • immunotherapy
HAVCR2(TIM-3):免疫检查点调控新机制及其在肿瘤治疗中的潜力
HAVCR2 (TIM-3): A novel mechanism of immune checkpoint regulation and its potential in tumor therapy
发布时间 2025-07-08
As an important member of the TIM family (TIM1/HAVCR1, TIM3/HAVCR2, TIM4/TIMD4), TIM-3 has attracted much attention for its critical role in autoimmune and tumor immune regulation
View details
  • Immunity/Inflamma
  • HAVCR2
  • TIM-3
  • PD-1
Total 5
  • 1
Go to